The United States Food and Drugs Administration (USFDA) has issued Establishment Inspection Report (EIR) to Shilpa Medicare’s 100% subsidiary -- Shilpa Pharma Lifesciences’ Unit-1 and the site is classified as Voluntary Action Indicated (VAI). The inspection was carried out at unit-1 by USFDA between March 3 to March 7, 2025.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
